Studying liver cancer response to targeted radiation therapy
Part of Cancer, Digestive system clinical trials.
This trial is for people with liver cancer (hepatocellular carcinoma) who are about to receive a type of internal radiation therapy called TARE (also known as radioembolization). Researchers want to learn more about how the cancer responds to this treatment using scans and biopsies. You might be a good fit if you have not had any prior treatment for your liver cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with liver cancer (hepatocellular carcinoma) by imaging and a biopsy.
- Your liver cancer has not been treated before, and you are scheduled to receive TARE (radioembolization).
- Your liver function is relatively good (Child-Pugh score below B8).
- You are able to have an MRI and a CT scan for the study.
- You are not pregnant, not breastfeeding, and agree to use effective birth control if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special PET scan (18F-FSPG) to help guide therapy for people with liver cancer (HCC) who are planning to receive Y90 radioembolization. The scan may help doctors better plan your treatment.
This trial tests a treatment called yttrium-90 carbon microsphere radioembolization for people with liver cancer that has been previously treated. Tiny radioactive beads are delivered directly to the tumor through the blood vessels to destroy cancer cells from inside. This may be an option if your liver cancer has not spread beyond the liver and you can tolerate the procedure.
This trial tests combining radiation therapy (radioembolization) with surgery to remove part of the liver for people with a single large liver tumor (over 8 cm) that hasn't spread. The goal is to see if this approach can treat the tumor effectively.
This trial tests a combination of focused radiation (SBRT), an immunotherapy drug (adelimumab), and a targeted therapy pill (apatinib) before surgery for liver cancer. The goal is to shrink tumors enough to make surgery possible or more effective.
This trial tests a targeted internal radiation treatment for people with liver cancer (HCC) that is too widespread for surgery and goes beyond the up-to-7 criteria. It aims to see if this therapy can safely and effectively treat tumors that are all located in a specific area of the liver.
This trial is testing a low 'scout' dose of tiny radioactive beads (resin microspheres) given into the liver to treat liver cancer. The goal is to see if this approach is safe and helps patients with certain types of liver cancer that cannot be surgically removed.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.